In light of the developing situation around COVID-19, Bristol Myers Squibb would like to share immediate action they are taking to support the health and well-being of patients, customers, and employees during this time.
Bristol Myers Squibb is expanding its longstanding patient support programs to help eligible unemployed patients in the U.S. who have lost their health insurance due to the COVID-19 pandemic. The expanded program offers access to BMS medicine for free.
Read the expanded patient support program overview.
The Community Oncology Alliance (COA) has partnered with CancerCare to provide free local transportation to patients during the COVID-19 national emergency. This program will provide free transportation for patients to and from their community oncology provider. Working with a nationwide transportation provider, practices will be able to organize free local transportation to and from appointments in clean vehicles.
Community oncology practices must register to be part of this program. Simply fill out this form and COA will provide you with details on how to book travel for patients needing transportation.
Genentech takes the health and safety of its patients, customers, employees, and local communities very seriously, and are actively responding to the global COVID-19 pandemic. Genentech knows that needs will continue to emerge over the coming weeks and months, and they are closely monitoring and evaluating the situation as it evolves.
For more information on Genentech's response to COVID-19, please visit its website.
As COVID-19 continues to have an increased impact on our communities, AbbVie continues its focus on the health and safety of employees, healthcare professionals, and patients. AbbVie is collaborating with select health authorities and institutions globally on clinical research related to COVID-19.
For more information on AbbVie's response to COVID-19, please visit its website.
Pfizer Oncology is pleased to announce that IBRANCE® (palbociclib) is transitioning from capsules to tablets. The new film-coated tablets will be dispensed in blister packs, whichh are designed to enable patients to track where they are in their treatment cycle. The tablet formulation is bioequivalent to the capsule formulation.
IBRANCE® is indicated for the treatment of adult patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced, or metastatic breast cancer in combination with:
an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men; or
fulvestrant in patients with disease progression following endocrine therapy.
Read the trade sheet for the tablet formulation.
On April 10, the U.S. Food and Drug Administration (FDA) approved KOSELUGO™(selumetinib) for the treatment of children two years of age and older with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas (PN) that cannot be completely removed by surgery.
Read corporate announcement.
Read product fact sheet.